IQV · Iqvia Holdings Inc. · Investor Relations

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Ari Bousbib, chairman and chief executive officer, will speak at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026, at 9:20 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com . A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high quality health data, Healthcare grade AI ® , advanced analytics, the latest technologies,

IQVIA Holdings Inc. (NYSE: IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today published its 2025 Sustainability Report. The report highlights IQVIA’s progress across its People, Public and Planet pillars, consistent with the company’s mission to accelerate innovation for a healthier world. IQVIA’s 2025 Sustainability Report can be downloaded at: https://www.iqvia.com/-/media/iqvia/pdfs/about-us/sustainability/iqvia-2025-sustainability-report.pdf . Highlights from the report include: Investments in the company’s employees. IQVIA’s approximately 93,000 employees worldwide are central to delivering on the company’s mission. In 2025, IQVIA accelerated learning and development opportunities through expanded AI and data analytics upskilling, generating more than 230,000 employee engagements with AI learning resources. More than 2,000 employees

IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced it has entered into an agreement to acquire certain discovery services assets from Charles River Laboratories. These assets include five sites specializing in a range of in vitro drug discovery services, including established laboratory based New Approach Methodologies (NAMs) and a small molecule AI platform, designed to accelerate discovery programs and support growing demand for non animal research methods. Collectively, these assets are underpinned by more than 20 years of curated scientific and operational data, as well as extensive therapeutic expertise. Since their inception, these assets have enabled over 100 molecules to enter clinical trials and include several commercially approved drugs. The acquisition complements IQVIA Laboratories’ existing drug discovery

IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Ron Bruehlman, chief financial officer, and Mike Fedock, senior vice president, financial planning & analysis and incoming CFO, will speak at Citi's 2026 Unplugged MedTech and Life Sciences Access Day on Thursday, February 26, 2026, at 11:00 a.m. ET. A live audio webcast of the presentation will be available on the IQVIA Investor Relations website at http://ir.iqvia.com . A replay of the webcast will be available later that day. About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on